SciELO - Scientific Electronic Library Online

 
vol.64 issue6Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control studyBody composition, but not insulin resistance, influences postprandial lipemia in patients with Turner's syndrome author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Archives of Endocrinology and Metabolism

Print version ISSN 2359-3997On-line version ISSN 2359-4292

Abstract

SCHEFFEL, Rafael Selbach et al. The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma. Arch. Endocrinol. Metab. [online]. 2020, vol.64, n.6, pp.751-757.  Epub Aug 28, 2020. ISSN 2359-4292.  https://doi.org/10.20945/2359-3997000000285.

Objective:

Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAFV600E mutation status on PTC risk stratification.

Subjects and methods:

PTC patients attending a university-based hospital who had the analysis of the BRAFV600E mutation were included. Persistent disease was defined as the presence of biochemical or structural disease. The performance of the ATA risk stratification system on predicting persistent disease with or without the BRAFV600E mutation status information was evaluated.

Results:

Of the 134 patients evaluated, 44 (32.8%) carried BRAFV600E mutation. The median tumor size was 1.7 cm (P25-75 1.0-3.0), 64 (47.8%) patients had lymph node, and 11 (8.2%) distant metastases. According to the ATA risk stratification system, patients were classified as low, intermediate, and high risk in 55 (41%), 59 (44%), and 20 (14%) patients, respectively. The data on BRAFV600E mutation reclassified 12 (8.9%) patients from low to intermediate risk. After a median follow-up of 8.5 years, the prevalence of persistent disease was similar in patients with and without BRAFV600E mutation (P = 0.42). Multivariate analysis failed to demonstrate an association between the BRAFV600E mutation and persistent disease status (RR 0.96; 95%CI 0.47-1.94). Notably, none of the patients reclassified from low to intermediate risk showed persistent disease on follow-up.

Conclusion:

Inclusion of BRAFV600E mutational status has a limited impact on risk stratification and does not add to the prediction of outcomes in PTC patients.

Keywords : Papillary thyroid carcinoma; BRAF mutation; risk classification; persistent disease.

        · text in English     · English ( pdf )